SRTA Strata Critical Medical (SRTA) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-health services · CIK 0001779128
Activist 13DForm 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
82
13F, latest reported quarter
What the filings say about SRTA
Insiders, 180 days
-$831.9K net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$517.0K
1 notice
Activist stakes (13D), 180 days
1 filing
Largest: 5.8% of the class
Strata Critical Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Strata Critical Medical, Inc. insiders sold a net $831.9K of stock across 12 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Nov 20, 2025.
- The trade is 3.5% of the 146,481 shares held after it.
- No other insider sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Love Reginald sold about $29.3K of SRTA on Aug 10, 2026; 82 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 9, 2025.
- The trade is 2.0% of the 1,548,997 shares held after it.
- 3 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-CEO and CFO Heyburn William A. sold about $185.9K of SRTA on Jun 8, 2026; 3 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 22, 2026.
- The trade is 3.2% of the 146,608 shares held after it.
- 3 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Cohen Amir sold about $27.3K of SRTA on Jun 8, 2026; 3 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.6% of the 1,892,774 shares held after it.
- 3 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-CEO and General Counsel Tomkiel Melissa M. sold about $174.5K of SRTA on Jun 8, 2026; 3 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.9% of the 625,574 shares held after it.
- 3 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, Logistics Wunsch Scott M sold about $32.6K of SRTA on Jun 8, 2026; 3 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$831.9K over 180 days
-$29.3K over 90 days
more than 54% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
82 funds bought in last quarter
below 69% of Healthcare Services
Revenue
+34.3% year over year
more than 83% of Healthcare Services
Margin
21.0% net margin
more than 96% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-27) · 5.0 days to cover · settled 2026-10-15
more than 65% of Healthcare Services
The situation: each line is one rule over one dataset
Third Point LLC disclosed a 5%+ stake (5.8%) in the last six months.
What changed in the last 30 days
Oct 15Third Point LLC filed a 13D for 5.8%
Oct 15Loeb Daniel S filed a 13D for 5.8%
Oct 2Former Boardmember The Eric L. Affeldt Living Trust DTD 2/14/2005 filed to sell $517.0K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch SRTA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.4%12M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SRTA: institutional holders (13F)
13F holdings, latest reported quarter
5,000,000 sh
$26.4M
4,890,584 sh
$25.8M
4,835,516 sh
$25.5M
4,629,228 sh
$24.4M
3,132,933 sh
$16.5M
Congress trades in SRTA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Third Point LLC
Activist 13D · 2026-10-15
5.8%
Loeb Daniel S
Activist 13D · 2026-10-15
5.8%
Krstic Velibor
Activist 13D · 2026-04-07
8.3%
SRTA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
The Eric L. Affeldt Living Trust DTD 2/14/2005
Filed 2026-10-02
$517.0K
SRTA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Smaller-Companies Growth Fund
$6.2M position · as of 2026-06-30
2.6%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$663.1K position · as of 2026-06-30
0.5%
BNY Mellon Small Cap Value Fund
$1.3M position · as of 2026-06-30
0.4%
Small Cap Portfolio
$1.6M position · as of 2026-06-30
0.4%
First Eagle Small Cap Opportunity Fund
$10.4M position · as of 2026-07-31
0.4%
Dunham Small Cap Value Fund
$329.7K position · as of 2026-07-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $831.9K sold by insiders over 180 days, 82 funds added last quarter, $517.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
SRTA financials
Revenue growth
+34.3%
XBRL, annual
Net margin
21.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM SRTA
| FY Dec 2025 | n/a |
| FY Dec 2024 | $248.7M |
| FY Dec 2023 | $225.2M |
| FY Dec 2022 | $146.1M |
| FY Sep 2021 | $50.5M |
| Jun 2026 | $72.5M |
| Mar 2026 | $67.4M |
| Dec 2025 | $66.8M |
| Sep 2025 | $49.3M |
| Jun 2025 | $70.8M |
| Mar 2025 | $54.3M |
| Dec 2024 | $54.4M |
| Sep 2024 | $74.9M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM SRTA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -11.0% |
| FY Dec 2023 | -24.9% |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | -14.5% |
| Mar 2026 | +3.2% |
| Dec 2025 | -13.2% |
| Sep 2025 | +116.5% |
| Jun 2025 | -5.3% |
| Mar 2025 | -6.4% |
| Dec 2024 | -18.0% |
| Sep 2024 | -2.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$48.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SRTA
| FY Dec 2025 | -$58.5M |
| FY Dec 2024 | -$33.4M |
| FY Dec 2023 | -$34.5M |
| FY Dec 2022 | -$37.9M |
| FY Sep 2021 | n/a |
| Jun 2026 | $3.2M |
| Mar 2026 | -$1.3M |
| Dec 2025 | -$10.2M |
| Sep 2025 | -$40.2M |
| Jun 2025 | -$5.3M |
| Mar 2025 | -$2.9M |
| Dec 2024 | -$6.3M |
| Sep 2024 | -$3.0M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2022-12-31 (42 months older than the period end); equity 2026-06-30
Debt to equity SRTA
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Sep 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt SRTA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+16.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SRTA
| FY Dec 2025 | +16.5% |
| FY Dec 2024 | -12.0% |
| FY Dec 2023 | -22.0% |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | +16.0% |
| Mar 2026 | +18.6% |
| Dec 2025 | +16.5% |
| Sep 2025 | +15.6% |
| Jun 2025 | -8.4% |
| Mar 2025 | -11.6% |
| Dec 2024 | -12.0% |
| Sep 2024 | -20.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+13.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SRTA
| FY Dec 2025 | +14.2% |
| FY Dec 2024 | -9.9% |
| FY Dec 2023 | -18.1% |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | +13.6% |
| Mar 2026 | +16.3% |
| Dec 2025 | +14.2% |
| Sep 2025 | +13.1% |
| Jun 2025 | -7.1% |
| Mar 2025 | -10.0% |
| Dec 2024 | -9.9% |
| Sep 2024 | -17.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SRTA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-7.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SRTA
| FY Dec 2025 | -8.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -24.4% |
| FY Dec 2022 | -17.2% |
| FY Sep 2021 | n/a |
| Jun 2026 | -7.9% |
| Mar 2026 | -7.3% |
| Dec 2025 | -8.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -23.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
9.71x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing SRTA
| FY Dec 2025 | 9.82x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | 10.76x |
| Mar 2026 | 7.46x |
| Dec 2025 | 9.82x |
| Sep 2025 | 10.33x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$404.8M
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term debt only, 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
Enterprise value SRTA
| FY Dec 2025 | $384.5M |
| FY Dec 2024 | $314.5M |
| FY Dec 2023 | $235.6M |
| FY Dec 2022 | $215.2M |
| FY Sep 2021 | n/a |
| Jun 2026 | $439.7M |
| Mar 2026 | $304.9M |
| Dec 2025 | $384.5M |
| Sep 2025 | $390.6M |
| Jun 2025 | $267.7M |
| Mar 2025 | $182.7M |
| Dec 2024 | $314.5M |
| Sep 2024 | $209.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-11.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield SRTA
| FY Dec 2025 | -14.1% |
| FY Dec 2024 | -10.0% |
| FY Dec 2023 | -13.1% |
| FY Dec 2022 | -14.8% |
| FY Sep 2021 | n/a |
| Jun 2026 | -10.6% |
| Mar 2026 | -15.7% |
| Dec 2025 | -14.1% |
| Sep 2025 | -13.2% |
| Jun 2025 | -5.3% |
| Mar 2025 | -9.1% |
| Dec 2024 | -10.0% |
| Sep 2024 | -15.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing SRTA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $197.1M | $248.7M | $225.2M | $146.1M |
| Gross profit | $41.1M | $29.6M | n/a | n/a |
| Operating income | -$22.4M | -$22.5M | -$68.1M | -$53.5M |
| Net income | $41.3M | -$27.3M | -$56.1M | -$27.3M |
| EPS (diluted) | 0.50 | -0.35 | -0.76 | -0.38 |
| Operating cash flow | -$48.9M | -$2.5M | -$32.3M | -$37.1M |
| Cash | $31.0M | $18.4M | $27.9M | $41.3M |
| Long-term debt | n/a | n/a | n/a | $0 |
| Buybacks | $0 | $244.0K | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SRTA Stock Sonar score 6/7 axes
Find similar shapesCompareSRTA ranks highest on financial health (99th percentile) and growth (83rd), and lowest on risk and compliance (17th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SRTA filings, in plain words
Are Strata Critical Medical insiders buying or selling SRTA?
In the 180 days to 2026-10-28, Strata Critical Medical insiders were net sellers, a net $831.9K across purchases and sales reported on Form 4, by 5 sellers.
Are there planned insider sales of SRTA?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $517.0K of stock; the latest, by The Eric L. Affeldt Living Trust DTD 2/14/2005, was filed 2026-10-02.
Read the full summary
In the 180 days to 2026-10-28, Strata Critical Medical insiders were net sellers of SRTA, a net $831.9K across purchases and sales reported on Form 4 by 5 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $517.0K of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.8% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
